Merck denies its new crown oral drug may cause viral mutations
Read Time:47 Second
According to the United Morning News, studies in the United States and the United Kingdom have shown that Merck’s new oral crown drug Lizoril (Lagevrio) has caused new viral mutations in some patients, and researchers are concerned that this could produce more contagious or health-threatening variants of the new crown virus. In response, Merck spokesman Robert Josephson said: “There is no evidence that any antiviral drug has caused the emergence of the variants currently in circulation …… Based on the available data, we believe that Lagevrio (Molnupiravir) is unlikely to have led to the emergence of a functioning viral variant.”
Current drug-related mutations have not been shown to be more likely to evade immune antibodies or to be more lethal, according to the study in question. The study was conducted by U.S. researchers as well as biological researchers from U.K. research institutions, including the Francis Crick Institute, Imperial College London and others.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating